System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Jean-Christophe Thery is an expert in Oncology at Centre Henri Becquerel (France). Jean-Christophe Thery has authored 67 publications, the most recent in 2026, and is an investigator in 14 clinical trials, 4 of them ongoing. SLR score: 339 (community average: 125). How the SLR is computed.

LeadR Profile

Jean-Christophe Thery Centre Henri Becquerel France
339 ScienceLeadR Reputation 339

Unlock

Register Login
Network Map

Oncology

Subspecialties: Biochemistry - Genetics - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2011 - 2026
Source: PubMed

Centre Henri Becquerel

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 67

Citations

Citations: 4 329 1st author: 3 Last author: 1 Unique author: 0

Main journals

J Clin Oncol 14
Ann Oncol 7
Cancer Res 6
Eur J Cancer 6
N Engl J Med 3

Best Journals

Ann Oncol 5
N Engl J Med 3
J Clin Oncol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Optimising rare tumour risk syndromes care: clinical insights and the PREVENTABLE socioeconomic framework.
PMID 42129296 — genetics, medical		Eur J Hum Genet20261
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort.
PMID 40967066 — breast neoplasms, neoplasms, disease progression, drug therapy, breast, therapeutics, chemotherapy		ESMO Open20250
Behavioural analysis of referral and uptake of care pathways for rare tumour risk syndromes: A cross-cultural mixed-methods study protocol within the PREVENTABLE project
OpenAlex W4409457572		Open Research Europe20250
Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy.
PMID 39742560 — immunohistochemistry, neoplasms, immunotherapy, sarcoma, tissues, msi-h		Eur J Cancer20242
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
PMID 39813643 — disease-free survival, breast neoplasms, neoplasms, maytansine, ado-trastuzumab emtansine, breast, therapeutics, trastuzumab		N Engl J Med Top journal202513

Clinical Studies 14

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 7
Phase 3 6
N/A 1

By status:

Completed 7
Recruiting 4
Active not recruiting 2
Unknown 1

By type:

Interventional 13
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 1
multicentricup10 12

Main Topics

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Phase Ib III Study of Capivasertib CDK4 6 Inhibitors Fulvestrant as Treatment for Advanced Metastatic HR HER2 Breast Cancer (CAPItello 292)
2023-504997-39-00 — genes, epidermal growth factor, fulvestrant, growth, breast neoplasms, neoplasms, hormones, receptors, growth factor, breast, therapeutics		Phase 3Active not recruiting2021
A Study to Learn About the Study Medicine Called PF 07220060 in Combination With Letrozole in People Over 18 Years of Age With HR Positive HER2 Negative Advanced Metastatic Breast Cancer who Have not Received any Prior Systemic Anticancer Treatment for Advanced Metastatic Disease (FourLight 3)
2024-512925-95-00 — breast neoplasms, neoplasms, letrozole, hormones, breast, therapeutics		Phase 3Recruiting2025
Treatment for breast cancer patients with meninges invaded by tumor cells
2022-502351-60-00 — cells, breast neoplasms, neoplasms, neoplasm metastasis, breast, meninges, therapeutics, capecitabine, trastuzumab		Phase 2Recruiting2024
Capecitabine Tucatinib and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
NCT05800275 — injections, meningeal neoplasms, breast neoplasms, spinal puncture, neoplasms, tablets, neoplasm metastasis, breast, punctures, capecitabine, meningeal carcinomatosis, trastuzumab		Phase 2Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS